• US business: Received approvals for 31 ANDAs/NDAs
  • Indian business: 170 brands (2 in Top 100) | 21st rank with 1.7% market share
    • Its prominent brands comprise Azithral (came into price control in FY14), Roxid, Wikoryl, and Althrocin.
    • Launched 22 brands in the Indian market across various therapeutic segments
  • Discontinued the manufacture of low-margin formulations in 2012-13, compensated by the production of high-value formulations for the US. 
  • Capex: Plans to expand their Formulation unit to 7 billion tablets /capsules pa in FY15. (Investment of 70crs only)
    • Plans to create a front-end marketing network in the US. (now this is a high-risk high return venture)
  • The API sales volume altered from a 50:20:30 (regulated markets: in-house consumption: other markets) in 2010-11 to 60:30:10 in 2013-14
  • Restructured the Indian front end: Altered their marketing model, balancing our product portfolio between divisions. 
    • They realigned MR goals, as a result of which focus shifted from a cumulative monthly sales target to brand-wise sales targets. 
    • 4000+ field forces cover 1.5 lakh doctors: Productivity is abysmal.
  • 350-person R&D team (added 50)